Swiss National Bank Has $35.24 Million Stock Position in Incyte Co. (NASDAQ:INCY)

Swiss National Bank decreased its stake in shares of Incyte Co. (NASDAQ:INCYFree Report) by 10.9% during the 3rd quarter, Holdings Channel reports. The firm owned 610,000 shares of the biopharmaceutical company’s stock after selling 74,400 shares during the period. Swiss National Bank’s holdings in Incyte were worth $35,240,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Clear Street Markets LLC increased its position in shares of Incyte by 93.6% during the 1st quarter. Clear Street Markets LLC now owns 362 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 175 shares during the last quarter. Parkside Financial Bank & Trust increased its holdings in shares of Incyte by 91.0% during the 1st quarter. Parkside Financial Bank & Trust now owns 447 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 213 shares during the last quarter. Glassman Wealth Services increased its holdings in shares of Incyte by 49.9% during the 2nd quarter. Glassman Wealth Services now owns 640 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 213 shares during the last quarter. Massmutual Trust Co. FSB ADV increased its holdings in shares of Incyte by 132.9% during the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 757 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 432 shares during the last quarter. Finally, Salem Investment Counselors Inc. increased its holdings in shares of Incyte by 1,458.0% during the 2nd quarter. Salem Investment Counselors Inc. now owns 779 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 729 shares during the last quarter. Institutional investors and hedge funds own 92.61% of the company’s stock.

Wall Street Analysts Forecast Growth

INCY has been the subject of several recent research reports. Royal Bank of Canada reduced their price target on Incyte from $74.00 to $63.00 and set a “sector perform” rating for the company in a research note on Wednesday, November 1st. Truist Financial restated a “buy” rating and issued a $91.00 price target on shares of Incyte in a research note on Wednesday, November 29th. StockNews.com upgraded Incyte from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, November 1st. William Blair restated an “outperform” rating on shares of Incyte in a research note on Tuesday. Finally, SVB Leerink upgraded Incyte from a “market perform” rating to an “outperform” rating and set a $78.00 target price for the company in a research report on Wednesday, December 13th. Eight investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $78.67.

View Our Latest Analysis on Incyte

Incyte Trading Up 0.0 %

NASDAQ INCY opened at $57.36 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.91 and a quick ratio of 3.86. Incyte Co. has a one year low of $50.27 and a one year high of $81.49. The business has a 50 day simple moving average of $60.96 and a 200 day simple moving average of $59.92. The stock has a market capitalization of $12.85 billion, a P/E ratio of 30.35, a P/E/G ratio of 0.63 and a beta of 0.67.

Insider Buying and Selling at Incyte

In other Incyte news, EVP Vijay K. Iyengar sold 657 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $65.00, for a total value of $42,705.00. Following the completion of the sale, the executive vice president now owns 43,412 shares of the company’s stock, valued at $2,821,780. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 17.50% of the company’s stock.

About Incyte

(Free Report)

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.

Featured Articles

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCYFree Report).

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.